Showing results (441-450 of 563) with videos related to

Sort By:
Pageof 57
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2026
131I-LNTH-1095 Radioligand Therapy Plus Enzalutamide vs. Enzalutamide Alone in Men With PSMA-Avid Metastatic Castration-Resistant Prostate Cancer: A Phase 2 StudyEvan Y Yu, Vivek Narayan, Giuseppe Esposito, et al.
The Journal of Urology|June 25, 2019
<sup>68</sup>Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective StudyAndrea Farolfi, Andrei Gafita, Jeremie Calais, et al.
Contemporary Clinical Trials|April 10, 2022
Defining optimal treatment for recurrent Clostridioides difficile infection (OpTION study): A randomized, double-blind comparison of three antibiotic regimens for patients with a first or second recurrenceStuart Johnson, Dale N Gerding, Xue Li, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 25, 2023
A VISION Substudy of Reader Agreement on <sup>68</sup>Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for <sup>177</sup>Lu-PSMA-617 Radioligand TherapyPhillip H Kuo, Don C Yoo, Ryan Avery, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 10, 2023
Is PSMA PET/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trialAdrien Holzgreve, Marcus Unterrainer, Jérémie Calais, et al.
The Journal of Allergy and Clinical Immunology. Global|October 2, 2023
Multisite evaluation of fire ant venom immunotherapy safety and efficacyHyun J Park, Nora L Watson, Robert H Wauters, et al.
Neuroscience Letters|September 4, 2017
Overexpression of Mitogen-activated protein kinase phosphatase-3 (MKP-3) reduces FoxO1 phosphorylation in mice hypothalamusBárbara de Almeida Rodrigues, Gabriel Keine Kuga, Vitor Rosetto Muñoz, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2018
Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug groupEmmanuel Meyer, David Pasquier, Guillemette Bernadou, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 6, 2017
Most of the Intended Management Changes After <sup>68</sup>Ga-DOTATATE PET/CT Are ImplementedJeremie Calais, Johannes Czernin, Matthias Eiber, et al.
European Urology|July 27, 2015
EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-GuérinSamantha Cambier, Richard J Sylvester, Laurence Collette, et al.
Pageof 57